FDA Requires Inovio to Submit Draft Voceryq Study Protocol by End of 2026
The FDA requires Inovio Pharmaceuticals to submit a draft protocol for Voceryq’s confirmatory study by the end of 2026.
The FDA requires Inovio Pharmaceuticals to submit a draft protocol for Voceryq’s confirmatory study by the end of 2026.